Featured Resources
-
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Case study
modalities
Biologics
Advancing biologics through cutting-edge design, structural biology, and chemistry for next-generation therapeutics.
supporting your research
Sygnature Discovery supports the full spectrum of biologics discovery from early concept through candidate nomination.
Our scientists draw on deep biological insight with practical expertise across bioscience, in vivo pharmacology, and DMPK to deliver innovation.
Working across oncology, inflammation, neuroscience, and metabolic disease, we design and optimize biologic molecules including monoclonal antibodies, peptides, nucleic acids, and cell and gene therapies that effectively translate from bench to clinic, ensuring a smooth and efficient path from idea to candidate.
Our Approach to Biologics Discovery
Every biologic demands a tailored strategy. Whether developing antibodies, peptides, nucleic acids, or cell and gene therapies, our multidisciplinary teams build robust, flexible workflows for each program.
Collaboration underpins everything we do, bioscientists, protein engineers, in vivo pharmacologists, and DMPK specialists work in unison to deliver rapid, decision-enabling data. By integrating scientific excellence with agility and partnership, we help clients realize the full potential of biologics.
how we can help
Protein and antibody engineering (bispecific and ADCs)
Peptide and peptide-drug conjugate design and synthesis
Computational and AI-driven optimization
Recombinant antibody production and purification
Mass spectrometry (intact, native, mapping)
Protein supply and purification for assays, HTS, diagnostics, and biophysics
X-ray crystallography, NMR, and cryo-EM for structural insight
Membrane protein and protein-ligand interaction expertise
Protein analysis and QC (Fida, SPR, SEC-MALS)
Scalable synthesis routes for conjugates and hybrid modalities
Expertise in gas-phase chemistries and complex molecule synthesis
Scale-up from milligrams to 100 grams for non-GLP safety studies
Custom assay cascades and in vivo models
Seamless integration of chemistry, bioscience, and DMPK
Proof-of-concept studies for clinical translation
X-ray crystallography with fragment hits from SPR and ASMS
Full fragment screening using in-house or external libraries
Why choose Sygnature Discovery?
We combine scientific depth, cutting-edge technology, and a collaborative mindset to help our partners unlock the promise of biologics. Working across key therapeutic areas, we deliver innovative solutions that go beyond traditional approaches, accelerating development and advancing novel modalities toward the clinic.
At Sygnature Discovery, we turn complex ideas into effective new medicines that change lives.
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Sitryx: Empowering New Ideas
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Corcept Therapeutics: Integrated Drug Discovery Collaboration
Corcept Therapeutics, located in Menlo Park, CA, is a leader in the discovery and development of drugs that regulate the effects of cortisol.
CellCentric Lead Optimisation Campaign – CCS1477
CellCentric are developing new treatments for cancer based on their understanding of epigenetics.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Hit Identification to 3 Compounds in the Clinic and 6 Development Candidates
UK-based small molecule drug discovery company
Focus on identifying novel treatments of inflammatory respiratory diseases, such as COPD
